Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P23760
UPID:
PAX3_HUMAN
Alternative names:
HuP2
Alternative UPACC:
P23760; G5E9C1; Q16448; Q494Z3; Q494Z4; Q53T90; Q6GSJ9; Q86UQ2; Q86UQ3
Background:
Paired box protein Pax-3, also known as HuP2, plays a pivotal role in neural development and myogenesis. It functions as a transcription factor, regulating cell proliferation, migration, and apoptosis. Pax-3 is a transcriptional activator of MITF, working synergistically with SOX10.
Therapeutic significance:
Pax-3 is implicated in several genetic disorders, including Waardenburg syndrome 1 and 3, Craniofacial-deafness-hand syndrome, and Rhabdomyosarcoma 2. These associations highlight its critical role in disease pathogenesis and underscore the potential of targeting Pax-3 in therapeutic strategies.